Camlodin® 5: Each tablet contains Amlodipine Besilate BP equivalent to 5 mg Amlodipine.
Amlodipine is a calcium antagonist of the dihydropyridine group & inhibits the transmembrane influx of calcium ion into cardiac & smooth muscle. It is used for the treatment of hypertension and angina pectoris.
Hypertension:
Camlodin® is indicated for the first line treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Chronic Stable Angina:
Camlodin® is indicated for the treatment of stable angina.
Camlodin® may be used alone or in combination with other antianginal agents.
Vasospastic Angina:
Camlodin® is indicated for the treatment of confirmed or suspected vasospastic angina.
Camlodin® may be used as monotherapy or in combination with other antianginal drugs.
The usual initial antihypertensive oral dose of Camlodin® is 5 mg once daily with a maximum dose of 10 mg once daily. Small, fragile or elderly individuals or patients with hepatic insufficiency may be started on 2.5 mg once daily dose and this dose may be used when adding Camlodin® to other antihypertensive therapy. Dosage should be adjusted according to each patient’s need.
The recommended dose for stable or vasospastic chronic angina is 5-10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency.
Digoxin: Absence of any interaction between Amlodipine and Digoxin in healthy volunteers has been documented in a controlled clinical study.
Warfarin: An unpublished study in healthy volunteers indicates that Amlodipine did not significantly alter the effect of Warfarin on prothrombin time.
Cimetidine: An unpublished clinical study indicated no interaction between Amlodipine & Cimetidine in healthy volunteers.
Food: Food does not alter the rate or extent of absorption of Amlodipine.
Generally since the vasodilatation induced by Amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of Amlodipine. Nonetheless caution should be exercised when administering Amlodipine with any other peripheral vasodilator particularly in patients with severe aortic stenosis.
Use in patients with congestive heart failure: Although haemodynamic studies and a controlled trial in class-II-III heart failure patients have shown that Amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology in general, all calcium channel blockers should be used with caution in patients with heart failure.
Beta-blocker withdrawal: Amlodipine is not a Beta-blocker and therefore gives no protection against the danger of abrupt Beta-blocker withdrawal; any such withdrawal should be gradual reduction of the doses of Beta-blocker.
Patients with hepatic failure: Since Amlodipine is extensively metabolised by the liver, in patients with impaired hepatic function caution should be exercised, when administering Amlodipine to patients with hepatic impairment.
Store in a dry place, at below 30° C. Protect from light and moisture. Keep out of the reach of children.